Skip to main content
Explore URMC

menu

Biliary Cancer: Phase 1b PEGPH20 with Cis & Gem; PEGPH20 with Atezolizumab, Cis & Gem; and compared with Cis & Gem alone in HA-High Subjects with Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Research Question:
What is the safety, tolerability and efficacy of PEGPH20 with Cis and Gem and PEGPH20 with Cis and Gem and Atezolizumab in comparison to Cis and Gem alone?

Basic Study Information

Purpose:
If you participate in the Run In portion of this study, you will be assigned to one of two treatment groups. You can be assigned to receive either PEGPH20 plus Cisplatin and Gemcitabine or PEGPH20 plus Cisplatin and Gemcitabine and Atezolizumab. If you participate in the Dose Expansion portion of the study, you will be assigned to one of three different treatment groups. You can be assigned to receive PEGPH20 plus Cisplatin and Gemcitabine, PEGPH20 plus Cistplatin and Gemcitabine and Atezolizumab or Cisplatin and Gemcitabine alone.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03267940?term=HALO-110&rank=1
Study Reference #: IGIB17085

Lead Researcher (Principal Investigator)

Lead Researcher: Marcus Noel

Study Contact Information

Study Coordinator: Chris Le Feber
Phone: (585) 275-0407
Email: Chris_LeFeber@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Adenocarcinoma

Return to Search